|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-2-4
|
|
pubmed:abstractText |
Cardiac sympathetic imaging with meta-iodobenzylguanidine (mIBG) is a noninvasive tool to risk stratify patients with heart failure (HF). In patients with ischemic and nonischemic cardiomyopathy, cardiac mIBG activity is a very powerful predictor of survival. Cardiac sympathetic imaging can help in understanding how sympathetic overactivity exerts its deleterious actions, which may result in better therapy and outcome for patients with HF.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1876-7591
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
92-100
|
|
pubmed:meshHeading |
pubmed-meshheading:20129538-3-Iodobenzylguanidine,
pubmed-meshheading:20129538-Arrhythmias, Cardiac,
pubmed-meshheading:20129538-Death, Sudden, Cardiac,
pubmed-meshheading:20129538-Female,
pubmed-meshheading:20129538-Heart,
pubmed-meshheading:20129538-Heart Failure,
pubmed-meshheading:20129538-Humans,
pubmed-meshheading:20129538-Male,
pubmed-meshheading:20129538-Middle Aged,
pubmed-meshheading:20129538-Predictive Value of Tests,
pubmed-meshheading:20129538-Radiopharmaceuticals,
pubmed-meshheading:20129538-Risk Assessment,
pubmed-meshheading:20129538-Sympathetic Nervous System,
pubmed-meshheading:20129538-Tomography, Emission-Computed,
pubmed-meshheading:20129538-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Cardiac sympathetic imaging with mIBG in heart failure.
|
|
pubmed:affiliation |
Hospital Sant Pau, Barcelona, Spain. icarrio@santpau.cat
|
|
pubmed:publicationType |
Journal Article,
Review
|
